Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.56 |
| ▸ | IDO1 | P14902 | 1/20 | 0.53 |
| ▸ | TDO2 | P48775 | 1/20 | 0.53 |
| ▸ | CES2 | O00748 | 2/20 | 0.51 |
| ▸ | ACP3 | P15309 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.49 |
| ▸ | DAO | P14920 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 2/20 | 0.48 |
| ▸ | HTR2C | P28335 | 2/20 | 0.48 |
| ▸ | HTR2B | P41595 | 2/20 | 0.48 |
| ▸ | MGLL | Q99685 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10110576 | 0.85 | PNMT (0.44) | PNMTIDO1TDO2CES2ACP3 | |
| SCHEMBL255035 | 0.84 | PNMT (0.55) | PNMTIDO1TDO2CES2ACP3 | |
| SCHEMBL2601113 | 0.84 | DAO (0.59) | PNMTIDO1TDO2CES2ACP3 | |
| SCHEMBL4086256 | 0.84 | PNMT (0.58) | PNMTIDO1TDO2CES2ACP3 | |
| SCHEMBL23343776 | 0.83 | PNMT (0.53) | PNMTIDO1TDO2CES2ACP3 | |
| SCHEMBL7626469 | 0.83 | PNMT (0.62) | PNMTIDO1TDO2CES2ACP3 | |
| SCHEMBL5848264 | 0.83 | PNMT (0.53) | PNMTIDO1TDO2CES2ACP3 | |
| SCHEMBL7336199 | 0.83 | PNMT (0.53) | PNMTIDO1TDO2CES2ACP3 | |
| Ammonia Solution, Strong SCHEMBL27629775 | 0.83 | PNMT (0.53) | PNMTIDO1TDO2CES2ACP3 | |
| SCHEMBL27946000 | 0.83 | PNMT (0.53) | PNMTIDO1TDO2CES2ACP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240154170-A1 | NONAQUEOUS ELECTROLYTE, NONAQUEOUS ELECTROLYTE SECONDARY BATTERY, AND ENERGY DEVICE | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-05-09 | — | — | US | disclosed |
| CN-111108642-B | Nonaqueous electrolyte, nonaqueous electrolyte secondary battery, and energy device | 三菱化学株式会社 | 2024-04-02 | — | — | CN | disclosed |
| CN-117790904-A | Nonaqueous electrolyte, nonaqueous electrolyte secondary battery, and energy device | 三菱化学株式会社 | 2024-03-29 | — | — | CN | disclosed |
| CN-115986213-A | Nonaqueous electrolyte solution and nonaqueous electrolyte battery | 三菱化学株式会社 | 2023-04-18 | — | — | CN | disclosed |
| EP-3780226-B1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY | MITSUBISHI CHEM CORP (JP) | 2022-05-11 | — | — | EP | disclosed |
| EP-3780226-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY | Mitsubishi Chemical Corporation (JP) | 2021-02-17 | — | — | EP | disclosed |
| US-20210020991-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2021-01-21 | — | — | US | disclosed |
| EP-3686983-A1 | NONAQUEOUS ELECTROLYTE, NONAQUEOUS ELECTROLYTE SECONDARY BATTERY, AND ENERGY DEVICE | Mitsubishi Chemical Corporation (JP) | 2020-07-29 | — | — | EP | disclosed |
| US-20200220222-A1 | NONAQUEOUS ELECTROLYTE, NONAQUEOUS ELECTROLYTE SECONDARY BATTERY, AND ENERGY DEVICE | MITSUBISHI CHEMICAL CORPORATION (JP) | 2020-07-09 | — | — | US | disclosed |
| CN-111108642-A | Nonaqueous electrolyte, nonaqueous electrolyte secondary battery, and energy device | 三菱化学株式会社 | 2020-05-05 | — | — | CN | disclosed |
| CN-110692160-A | Nonaqueous electrolyte solution and nonaqueous electrolyte battery | 三菱化学株式会社 | 2020-01-14 | — | — | CN | disclosed |
| CN-104245702-A | Novel neurokinin 1 receptor antagonist compounds | LEO PHARMA AS | 2014-12-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210020991-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY | SLC9B2, SLC9A1, SLC9A2 | PNMT 4050/4885IDO1 4860/4885TDO2 4118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.